Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BioTech Medics, Inc. (BMCS)
Southlake, TX, US
BioTech Medics, Inc. operates as a holding company with a focus on the medical field. The firm manages therapeutic laser clinics that deliver treatment for diverse pain conditions impacting muscles, nerves, bones, and arthritic discomfort. Among its product offerings is SHBAN, an antiseptic sanitizing solution for hands and body. Additionally, the company develops and markets nutritional supplements, including BioBody Balance, a concentrated liquid vitamin, and BioBody Energy Spray, a natural, caffeine- and alcohol-free vitamin energy spray. These nutraceutical products are distributed via general retail channels. Founded in 1997 and headquartered in Southlake, Texas, BioTech Medics maintains laser pain centers across Texas, California, New Mexico, and Florida.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | 0.00% | -72.73% | -72.73% | -96.34% | -96.25% | -97.86% | +50.00% | -99.45% | -88.00% | -99.21% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%—
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%— Q1'25: +100.0% (vs Q1'24)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%—
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%—
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+0.0% Q1'25: 0.0% (vs Q1'24)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'25: +0.0% (vs Q1'24)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.69× Q1'25: -0.15× (vs Q1'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Anthony Keith Miller | Chief Executive Officer | — | — |
| James C. Nairne | Chief Financial Officer | — | male |
| Keith A. Houser | Chairman & Interim President | — | male |
| Tom Wood | Senior Vice President of Sales | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BMCS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
